Study links Avandia to increased bone fracture risk

12/2/2007 | Forbes

A new study suggests long-term use of GlaxoSmithKline's diabetes drug Avandia may increase bone loss in diabetes patients. The study, conducted on mice, suggests Avandia -- which earlier was found to suppress bone-building osteoblasts -- also stimulates the action of osteoclasts, cells that naturally degrade bone. "Because Avandia is effective in controlling glucose and restoring the body's sensitivity to insulin, we do not recommend that people stop their treatment," the lead author cautioned.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA